Ocular announces ‘retina dream team’ and $325 million financing

23 February 2024

Ophthalmology company Ocular Therapeutix (Nasdaq: OCUL) has named what it describes as a ‘retina dream team’ alongside its announcement of a $325 million financing.

Both are expected to accelerate the momentum of Axpali (axitinib intravitreal implant), in the first of two Phase III trials for wet age-related macular degeneration (wet AMD).

"We believe our expanded leadership team will enable us to potentially accelerate the pace of our clinical program for Axpali"Industry veteran Pravin Dugel becomes the company’s executive chairman while Jeffrey Heier, Peter Kaiser, and Sanjay Nayak join the Ocular management team as chief scientific officer, medical director and chief strategy officer, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK